NCT04020783 Primary Aldosteronism: Prospective Screening Registry in China
| NCT ID | NCT04020783 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Condition | Primary Aldosteronism |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2018-07-18 |
| Primary Completion | 2024-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2018-07-18 with a primary completion date of 2024-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Study name: A prospective study of the incidence and outcomes of Primary aldosteronism in Chinese hypertensive patients 2. Rationale: Unlike essential hypertension, secondary hypertension is caused by certain defined diseases or causes. For this reason, secondary hypertension can often be cured or effectively controlled. As one of the most common types of secondary hypertension, it is estimated that primary aldosteronism (PA) accounts for 5%-10% of all hypertensive patients, accounting for about 20% of patients with refractory hypertension. 3. Objective: 1) Collect and analyze the population and disease characteristics of Chinese PA patients; 2) Strengthen the awareness of screening for PA in people with high blood pressure. 4. Study design: Prospective , multi-center, observational study. 5. Study population: Hypertensive patients with high suspected or confirmed of primary aldosteronism. 6. Treatment: Standardized diagnosis and treatment procedure as recommended in the international guidelines of PA. 7. Follow up: 6, 12 and 24 months after diagnosis. 8. Sample size estimation: About 10 thousand. 9. Timeline: Start of subjects enrollment: July 2019; End of subjects enrollment: December 2022; End of study: December 2024. 10. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.
Eligibility Criteria
Eligibility criteria 1. Age: more than or equal to 18 years old; 2. Hypertensive patients ; 3. ARR \> 40; 4. Informed consent; Exclusion criteria: Not eligible for inclusion or in situations considered unqualified for the study by the investigator.
Contact & Investigator
Jiguang Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Frequently Asked Questions
Who can join the NCT04020783 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Primary Aldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04020783 currently recruiting?
Yes, NCT04020783 is actively recruiting participants. Contact the research team at jiguangw@163.com for enrollment information.
Where is the NCT04020783 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04020783 clinical trial?
NCT04020783 is sponsored by Shanghai Jiao Tong University School of Medicine. The principal investigator is Jiguang Wang, MD, PhD at Shanghai Jiao Tong University School of Medicine, Ruijin Hospital. The trial plans to enroll 10,000 participants.